IP Library Granted Patent US 10,647,713
Granted Patent B2
US 10,647,713 · App. 15/789,588 · Granted May 12, 2020

TYK2 inhibitors and uses thereof

Inventors: Jeremy Robert Greenwood (Brooklyn, NY); Silvana Marcel Leit de Moradei (Burlington, MA); Craig E. Masse (Cambridge, MA); Thomas H. McLean (Cambridge, MA); Sayan Mondal (New York, NY)
Assignee: Nimbus Lakshmi, Inc.
C07D471/04A61P3/10A61P5/26A61P25/28A61P35/02A61P37/00C07D473/28C07D473/32C07D473/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,647,713
App. No.
15/789,588
Granted
May 12, 2020
Kind
B2
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Claims (670)

1. A compound of formula I′:

or a pharmaceutically acceptable salt thereof, wherein:

X is N or C(R 3 );

R 1 is —CH 2 F, —CHF 2 , —NRR D , —N(R D ) 2 , or —OR D ;

R 2 is H, R C , —N(R)C(O)Cy 2 , —N(R)S(O) 2 Cy 2 , —N(R)Cy 2 , —OCy 2 , —SCy 2 , or Cy 2 ;

R 3 is H, halogen, or C 1-6 aliphatic; or

R 2 and R 3 are taken together with their intervening atoms to form a 4-7 membered partially unsaturated or aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein said ring is substituted with m instances of R 4 ;

each of Cy 1 and Cy 2 is independently phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Cy 1 is substituted with n instances of R 5 ; and; wherein Cy 2 is substituted with p instances of R 6 ;

L 1 is a covalent bond or a C 1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by C(R 7 ) 2 —, N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O) 2 —, —S(O) 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or —S(O) 2 —;

each instance of R 4 , R 5 , R 6 , and R 7 is independently R A or R B , and is substituted by q instances of R C ;

each instance of R A is independently oxo, halogen, —CN, —NO 2 , —OR, —OR D , —SR, —NR 2 , —S(O) 2 R, —S(O)(NR)R, —S(O) 2 NR 2 , —S(O)R, —S(O)NR 2 , —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)C(NR)NR 2 , —N(R)S(O) 2 NR 2 , —N(R)S(O) 2 R, —N(R D )S(O) 2 R, —N(R)S(O) 2 R D , —N(R D )S(O) 2 R D , or —P(O)R 2 ;

each instance of R B is independently C 1-6 aliphatic; phenyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each instance of R c is independently oxo, halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —S(O)NR 2 , —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)C(NR)NR 2 , —N(R)S(O) 2 NR 2 , or —N(R)S(O) 2 R or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

R D is a C1-4 aliphatic group wherein one or more hydrogens are replaced by deuterium;

each R is independently hydrogen, or an optionally substituted group selected from C1.6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and each of m, n, p, and q is independently 0, 1, 2, 3, or 4.

2. The compound of claim 1 of formula I-a:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 of formula I-b or I-c:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 of formula II-a or II-b:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 of formula III-a or III-b:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 of formula V-a, V-b, V-c, V-d, V-e, V-f, V-g, V-h, V-i, V-j, V-k, V-l, V-m, V-n, V-o, V-p, V-q or V-r:

or a pharmaceutically acceptable salt thereof.

7. The compound of any of claims 1 - 6 , wherein Cy 2 is selected from the following:

each of which is substituted by p instances of R 6 .

8. The compound of claim 7 wherein R 2 is —N(H)Cy 2 or —N(H)C(O)Cy 2 .

9. The compound of claim 8 wherein R 2 is

10. The compound of claim 9 wherein R 3 is H.

11. A compound selected from those depicted below, or a pharmaceutically acceptable salt thereof:

Compound

Structure

I-1

I-2

I-3

I-4

I-5

I-6

I-7

I-8

I-9

I-10

I-11

I-12

I-13

I-14

I-15

I-16

I-17

I-18

I-19

I-20

I-21

I-22

I-23

I-24

I-25

I-26

I-27

I-28

I-29

I-30

I-31

I-32

I-33

I-34

I-35

I-36

I-37

I-38

I-39

I-40

I-41

I-42

I-43

I-44

I-45

I-46

I-47

I-48

I-49

I-50

I-51

I-52

I-53

I-54

I-55

I-56

I-57

I-58

I-59

I-60

I-61

I-62

I-63

I-64

I-65

I-78

I-79

I-80

I-81

I-82

I-83

I-84

I-85

I-86

I-87

I-88

I-89

I-90

I-91

I-92

I-93

I-94

I-95

I-96

I-97

I-98

I-100

I-101

I-103

I-104

I-105

I-107

I-108

I-109

I-110

I-111

I-112

I-113

I-114

I-115

I-116

I-117

I-118

I-120

I-121

I-122

I-123

I-124

I-125

I-126

I-127

I-128

I-129

I-130

I-131

I-132

I-133

I-134

I-135

I-136

I-137

I-138

I-139

I-140

I-141

I-142

I-143

I-144

I-145

I-146

I-147

I-148

I-149

I-150

I-151

I-152

I-153

I-154

I-155

I-156

I-157

I-158

I-159

I-160

I-161

I-162

I-163

I-164

I-165

I-166

I-167

I-168

I-169

I-170

I-171

I-172

I-173

I-174

I-175

I-176

I-178

I-179

I-180

I-181

I-182

I-183

I-184

I-185

I-186

I-187

I-188

I-189

I-190

I-191

I-192

I-193

I-194

I-195

I-196

I-197

I-198

I-199

I-200

I-201

I-202

I-203

I-204

I-205

I-206

I-207

I-208

I-209

I-210

I-211

I-212

I-213

I-214

I-210

I-211

I-212

I-213

I-214

I-215

I-216

I-217

I-218

I-219

I-220

I-221

I-222

I-223

I-224

I-225

I-226

I-227

I-228

I-229

I-230

I-231

I-232

I-233

I-234

I-235

I-236

I-237

I-238

I-239

I-240

I-241

I-242

I-243

I-244

I-245

I-246

I-247

I-248

I-249

I-250

I-251

I-252

I-253

I-254

I-255

I-256

I-257

I-258

I-259

I-260

I-261

I-262

I-263

I-264

I-265

I-266

I-267

I-268

I-269

I-270

I-271

I-272

I-273

I-274

I-275

I-276

I-277

I-278

I-279

I-280

I-281

I-282

I-283

I-284

I-285

I-286

I-287

I-288

I-289

I-290

I-291

I-292

I-293

I-294

I-295

I-296

I-297

I-298

I-299

I-300

I-301

I-302

I-303

I-304

I-305

I-306

I-307

I-308

I-309

I-310

I-311

I-312

I-313

I-314

I-315

I-316

I-317

I-318

I-319

I-320

I-321

I-322

I-323

I-324

I-325

I-326

I-327

I-328

I-329

I-330

I-331

I-332

I-333

I-334

I-335

I-336

I-337

I-338

I-339

I-340

I-341

I-342

I-343

I-344

I-345

I-346

I-347

I-348

I-349

I-350

I-351

I-352

I-353

I-354

I-355

I-356

I-357

I-358

I-359

I-360

I-361

I-362

I-363

I-364

I-365

I-366

I-367

I-368

I-369

I-370

I-371

I-372

I-373

I-374

I-375

I-376

I-377

I-378

I-379

I-380

I-381

I-382

I-383

I-384

I-385

I-386

I-387

I-388

I-389

I-390

I-391

I-392

I-393

I-394

I-395

I-396

I-397

I-398

I-399

I-400

I-401

I-402

I-403

I-404

I-405

I-406

I-407

I-408

I-409

I-410

I-411

I-412

I-413

I-414

I-415

I-416

I-417

I-418

I-419

I-420

I-421

I-422

I-423

I-424

I-425

I-426

I-427

I-428

I-429

I-430

I-431

I-432

I-433

I-434

I-435

I-436

I-437

I-438

I-439

I-440

I-441

I-442

I-443

I-444

I-445

I-446

I-447

I-448

I-449

I-450

I-451

I-452

I-453

I-454

I-455

I-456

I-457

I-458

I-459

I-460

I-461

I-462

I-463

I-464

I-465

I-466

I-467

I-468

I-469

I-470

I-471

I-472

I-473

I-474

I-475

I-476

I-477

I-478

I-479

I-480

I-481

I-482

I-483

I-484

I-485

I-486

I-487

I-488

I-489

I-490

I-491

I-492

I-493

I-494

I-495

I-496

I-497

I-498

I-499

I-500

I-501

I-502

I-503

I-504

I-505

I-506

I-507

I-508

I-509

I-510

I-511

I-512

I-513

I-514

I-515

I-516

I-517

I-518

I-519

I-520

I-521

I-522

I-523

I-524

I-525

I-526

I-527

I-528

I-529

I-530

I-531

I-532

I-533

I-534

I-536

I-537

I-538

I-539

I-540

I-541

I-542

I-543

I-544

I-545

I-546

I-547

I-548

I-549

I-550

I-551

I-552

I-553

I-554

I-555

I-556

I-557

I-558

I-559

I-560

I-561

I-562

I-563

I-564

I-565

I-566

I-567

I-568

I-569

I-570

I-571

I-572

I-573

I-574

I-575

I-576

I-577

I-578

I-579

I-580

I-581

I-582

I-583

I-584

I-585

I-586

I-587

I-588

I-589

I-590

I-591

I-592

I-593

I-594

I-595

I-596

I-597

I-598

I-599

I-601

I-602

I-604

I-605

I-606

I-607

I-608

I-609

I-610

I-611

I-612

I-613

I-614

I-615

I-616

I-617

I-618

I-619

I-620

I-621

I-622

I-623

I-624

I-625

I-626

I-627

I-628

I-629

I-630

I-631

I-632

I-633

I-634

I-635

I-636

I-637

I-638

I-639

I-640

I-641

I-642

I-643

I-644

I-645

I-646

I-647

I-648

I-649

I-650

12. A pharmaceutical composition comprising a compound according to any one of claim 1 - 6 or 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (15)
INTERCOMPANY AGREEMENT Recorded Sep 11, 2023
From: NIMBUS LAKSHMI, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 064867/0415 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME AND APPLICATION NUMBER 15879588 PREVIOUSLY RECORDED AT REEL: 048305 FRAME: 0181. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Oct 12, 2021
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, L.L.C.
Reel/Frame 057787/0102 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 15879588 PREVIOUSLY RECORDED AT REEL: 048308 FRAME: 0520. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Oct 12, 2021
From: SCHRÖDINGER, L.L.C.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 057787/0140 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 15879588 PREVIOUSLY RECORDED AT REEL: 048306 FRAME: 0430. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Oct 12, 2021
From: GREENWOOD, JEREMY ROBERT
To: SCHRÖDINGER, INC.
Reel/Frame 057786/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: SCHRODINGER, INC.
To: SCHRODINGER, L.L.C.
Reel/Frame 049062/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: SCHRODINGER, L.L.C.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 049062/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: LEIT DE MORADEI, SILVANA MARCEL
To: NIMBUS DISCOVERY, INC.
Reel/Frame 049059/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: MASSE, CRAIG E.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 049059/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: MCLEAN, THOMAS
To: NIMBUS DISCOVERY, INC.
Reel/Frame 049059/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: MONDAL, SAYAN
To: SCHRODINGER, INC.
Reel/Frame 049059/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: NIMBUS DISCOVERY, INC.
To: NIMBUS LAKSHMI, INC.
Reel/Frame 049059/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2019
From: GREENWOOD, JEREMY ROBERT
To: SCHRODINGER, INC.
Reel/Frame 049062/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2019
From: SCHRODINGER, INC.
To: SCHRODINGER, L.C.C.
Reel/Frame 048305/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2019
From: SCHRODINGER, L.L.C.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 048308/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2019
From: GREENWOOD, JEREMY ROBERT
To: SCHRODINGER, INC.
Reel/Frame 048306/0430 →
Continuity (7)
Provisional Application 62411194 · Oct 21, 2016
Provisional Application 62468789 · Mar 8, 2017
Provisional Application 62546422 · Aug 16, 2017
Provisional Application 62560607 · Sep 19, 2017
Provisional Application 62468728 · Mar 8, 2017
Provisional Application 62560610 · Sep 19, 2017
Related Publication 20180134700A1 · May 17, 2018
Cited By (1)
US 12,221,453